ALSO NOTED: Sciele taps new president and COO; GSK licenses Santarus heartburn drugs

> Sciele Pharma appointed Edward J. Schutter as its new president and chief operating officer. He had been an EVP and chief commercial officer. Report

> Scientists have re-engineered the blockbuster oncology drug Gleevec to eliminate a serious cardiovascular risk, taking a new approach that could offer a significant improvement for "hundreds" of other drugs as well. Report

> GlaxoSmithKline inked a deal to sell Santarus' heartburn drugs in up to 114 countries, in return for an $11.5 million up-front payment plus royalties. Report

> Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Report

> The European Committee for Medicinal Products for Human Use (CHMP) gave its blessing to early use of Bayer's Betaferon against multiple sclerosis; currently the drug is approved for treatment in the disease's more advanced stages. Report

> California-based device maker Sutura and Abbott Laboratories have made a cross-licensing deal to settle patent infringement litigation. Report

And Finally... It's not fat but fitness that predicts longevity in adults over the age of 60. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.